Normal testosterone levels in males

What Is a Normal Testosterone Level for Young Men? Rethinking the 300 ng/dL Cutoff for Testosterone Deficiency in Men 20-44 Years Old

Purpose: There is an age-related decline in male testosterone production. It is therefore surprising that young men are evaluated for testosterone deficiency with the same cutoff of 300 ng/dL that was developed from samples of older men. Our aim is to describe normative total testosterone levels and age-specific cutoffs for low testosterone levels in men 20 to 44 years old.

Materials and methods: We analyzed the 2011-2016 National Health and Nutrition Examination Surveys, which survey nationally representative samples of United States residents. Men 20 to 44 years old with testosterone levels were included. Men on hormonal medications, with a history of testicular cancer or orchiectomy, and with afternoon/evening laboratory values were excluded. We separated men into 5-year intervals and evaluated the testosterone levels of each age group, and for all men 20 to 44 years old. We used the American Urological Association definition of a “normal testosterone level” (the “middle tertile”) to calculate age-specific cutoffs for low testosterone levels.

Results: Our final analytic cohort contained 1,486 men. Age-specific middle tertile levels were 409-558 ng/dL (20-24 years old), 413-575 ng/dL (25-29 years old), 359-498 ng/dL (30-34 years old), 352-478 ng/dL (35-39 years old), and 350-473 ng/dL (40-44 years old). Age-specific cutoffs for low testosterone levels were 409, 413, 359, 352, and 350 ng/dL, respectively.

Conclusions: Diagnosis of testosterone deficiency has traditionally been performed in an age-indiscriminate manner. However, young men have different testosterone reference ranges than older men. Accordingly, age-specific normative values and cutoffs should be integrated into the evaluation of young men presenting with testosterone deficiency.

Keywords: hypogonadism; testosterone.

Comment in

Tadros N. Tadros N. J Urol. 2022 Dec;208(6):1302. doi: 10.1097/JU.0000000000002928.02. Epub 2022 Oct 25. J Urol. 2022. PMID: 36282058 No abstract available.

Campbell KJ. Campbell KJ. J Urol. 2022 Dec;208(6):1301. doi: 10.1097/JU.0000000000002928.01. Epub 2022 Oct 25. J Urol. 2022. PMID: 36282059 No abstract available.

Similar articles

Madhusoodanan V, Patel P, Lima TFN, Gondokusumo J, Lo E, Thirumavalavan N, Lipshultz LI, Ramasamy R. Madhusoodanan V, et al. Int Braz J Urol. 2019 Sep-Oct;45(5):1008-1012. doi: 10.1590/S1677-5538.IBJU.2019.0132. Int Braz J Urol. 2019. PMID: 31408289 Free PMC article.

Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG. Morgentaler A, et al. J Sex Med. 2014 Nov;11(11):2818-25. doi: 10.1111/jsm.12657. Epub 2014 Aug 18. J Sex Med. 2014. PMID: 25131184 Clinical Trial.

Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM. Bhattacharya RK, et al. Clin Interv Aging. 2012;7:321-30. doi: 10.2147/CIA.S32036. Epub 2012 Aug 24. Clin Interv Aging. 2012. PMID: 22956867 Free PMC article.

Raheem OA, Chen T, Akula KP, Greenberg J, Le TV, Chernobylsky D, Sikka SC, Walsh TJ. Raheem OA, et al. Sex Med Rev. 2021 Jul;9(3):381-392. doi: 10.1016/j.sxmr.2020.08.003. Epub 2021 Apr 29. Sex Med Rev. 2021. PMID: 33933392 Review.

Schmidtova E, Kelemenova S, Ostatnikova D. Schmidtova E, et al. Bratisl Lek Listy. 2009;110(12):765-72. Bratisl Lek Listy. 2009. PMID: 20196470 Review.

Cited by

Stewart KL, Lephart ED. Stewart KL, et al. Int J Mol Sci. 2023 Mar 13;24(6):5486. doi: 10.3390/ijms24065486. Int J Mol Sci. 2023. PMID: 36982560 Free PMC article. Review.

Cheap Canadian Pharma LLC. 775 Cambie St, Vancouver, BC, Canada. All Rights Reserved.